Login
Manage Portfolio
Post a StockTalk
Write an Instablog
Get Daily Email Alert
Seeking Alpha
Home
The Macro View
Stocks & Sectors
Global Markets
ETFs
Investing Ideas
Breaking News
Transcripts
Business Intelligence
Merck KGAA U/ADR (MKGAY.PK)
(
)
Quotes
Dashboard
Chart
Historical Prices
Options
Analysis
Articles
Instablogs
StockTalks
Sentiment
Comments
News & PR
Market Currents
Buzz
Twitter: MKGAY.PK
Coverage
Top Authors
Cramer
Top Analysts
Business Intelligence
Transcripts
Events
Key Developments
Earnings
History & Projected
Consensus
Peer Earnings
Filings
SEC Filings
Annual Report
Ownership
Major Holders
Insider Trades
Insider Sentiment
Index Membership
Short Interest
Financials
Income Statement
Balance Sheet
Cash Flow
Company
Wikipedia Profile
Officers & Directors
Executive Comp
52wk high:
52wk low:
EPS:
PE:
Dividend:
Yield:
Market Cap:
Exchange:
Analysis - Latest Articles
Novartis: Powering into the Multiple Sclerosis Market
Richard Sater
•
Sep 08
•
3 Comments
BioMS: Hype or Hope?
Richard Sater
•
Jul 13
•
14 Comments
FDA Calendar Updates: Amgen, Amicus, Oncothyreon and Medarex
Mike Havrilla
•
Jun 23
•
1 Comment
Long Term Results of Oncothyreon's Stimuvax Look Promising
VFC's Stock House
•
May 31
•
4 Comments
New MS Therapies: A Hard Pill to Swallow?
Richard Sater
•
Apr 19
•
5 Comments
Tracking Cancer Diagnostic and Therapeutic Stocks
Mike Havrilla
•
Apr 13
•
6 Comments
More articles on MKGAY.PK »
Instablogs
Novartis: Powering into the MS market
Mon September 7, 2009
•
Richard Sater
•
Comment!
BioMS: Hype or Hope
Sun July 12, 2009
•
Richard Sater
•
2 Comments
FDA Calendar Updates: EURX, AMGN, FOLD, ONTY, MEDX
Mon June 22, 2009
•
Mike Havrilla
•
Comment!
Write a post on MKGAY.PK
|
More Instablogs on MKGAY.PK »
Sentiment
What advice would you give to
MKGAY.PK?
119 characters left
What's your view of MKGAY.PK?
Make sure you include MKGAY.PK
140 characters left
|
Settings